Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

@article{Weber2008OvercomingIT,
  title={Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).},
  author={Jeffrey S. Weber},
  journal={The oncologist},
  year={2008},
  volume={13 Suppl 4},
  pages={16-25}
}
Targeted biologic therapies such as anti-cytotoxic T lymphocyte antigen (CTLA-4) monoclonal antibodies, either as monotherapy or in combination with chemotherapy or vaccines, have shown great promise in late-stage melanoma, which has a very poor prognosis. Melanoma is relatively resistant to both chemotherapy and radiotherapy. Blockade of CTLA-4, which inhibits T-cell proliferation, promotes stimulation of adaptive immunity and T-cell activation, resulting in eradication of tumor cells. Two… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Disease control and long-term survival in chemotherapy-naïve patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine

  • EM Hersh, JS Weber, JD Powderly
  • J Clin Oncol 2008;26:488s
  • 2008

Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

  • O Hamid, K Chin, J Li
  • J Clin Oncol 2008;26:489s
  • 2008

Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies

  • SJ O’Day, R Ibrahim, V DePril
  • J Clin Oncol 2008;26:488s
  • 2008

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an antiCTLA-4 monoclonal antibody

  • FS Hodi, A Hoos, R Ibrahim
  • J Clin Oncol 2008;26:134s
  • 2008

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  • A Ribas, R Hauschild, CJ Kefford
  • J Clin Oncol 2008;26:485s
  • 2008

Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma

  • JS Weber, D Berman, J Siegel
  • J Clin Oncol 2008;26:485s
  • 2008

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

  • O Hamid, WJ Urba, M Yellin
  • J Clin Oncol 2007;25:478s
  • 2007

Similar Papers

Loading similar papers…